ANGPT1
ANGPT1 (Angiopoietin-1) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Overview
Binds and activates TEK/TIE2 receptor by inducing its dimerisation and tyrosine phosphorylation. Plays an important role in the regulation of angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganisation of the actin cytoskeleton, but also maintenance of vascular quiescence. Required for normal angiogenesis and heart development during embryogenesis.
Open Targets scores its association with cancer at 0.51 (direct and indirect evidence; datatypes literature 0.97, genetic association 0.44, clinical 0.68).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ANGPT1 (Angiopoietin-1) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
- 1 · What it is
ANGPT1 (Angiopoietin-1) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
- 2 · What goes wrong in cancer
Binds and activates TEK/TIE2 receptor by inducing its dimerisation and tyrosine phosphorylation.
- 3 · How drugs use it
No product in this corpus aims at ANGPT1 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:484 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q15389 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000154188 (association with cancer (MONDO_0004992) 0.51; (GraphQL API, CC0))
Biology
Binds and activates TEK/TIE2 receptor by inducing its dimerisation and tyrosine phosphorylation. Plays an important role in the regulation of angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganisation of the actin cytoskeleton, but also maintenance of vascular quiescence. Required for normal angiogenesis and heart development during embryogenesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signalling cascades. Location: Secreted (UniProt). Locus 8q23.1 (HGNC).
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.68. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ANGPT1" OR ABSTRACT:"ANGPT1" OR TITLE:"angiopoietin 1" OR ABSTRACT:"angiopoietin 1" OR TITLE:"Angiopoietin-1" OR ABSTRACT:"Angiopoietin-1" OR TITLE:"KIAA0003" OR ABSTRACT:"KIAA0003" OR TITLE:"Ang1" OR ABSTRACT:"Ang1" OR TITLE:"AGPT-1" OR ABSTRACT:"AGPT-1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ANGPT1, not a curated reading list.